The effect of hematopoietic growth factors on platelet aggregability

Clinical and Applied Thrombosis/Hemostasis

Volumn 4, Issue 4, 1998, Pages 238-242

  Kaplan, Alexander ^a   Kaplan, Svetlana ^a   Marcoe, Karen F ^a   Sauvage, Lester R ^b   Hammond, William P ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c HOPE HEART INSTITUTE   (United States)

Author keywords

Hematopoietic growth factors; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; THROMBOPOIETIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ERYTHROPOIESIS; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

EID: 0031710079     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969800400404     Document Type: Article

References (45)

1. Gabrilove JL, Jakubowski A, Scher H, et al. Granulocyle colony stimulating factor reduces neutropenia and associated morbidity of chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988;318:1414.
2. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809.
3. Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1988;58:64.
4. Morstyn G, Campbell I, Lieschke G, et al. Treatment of chemotherapy-induced neutropenia by subcutaneous administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989;7:1554.
5. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988;319:593.
6. Morstyn G, Stuart-Harris R, Bishop J, et al. Optimal scheduling of granulocyte-macrophage colony-stimulating factor (GM-CSF) for the abrogation of chemotherapy-induced neutropenia in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1989;8:850.
7. Gianni AM, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990;8:868.
8. Barlogie B, Jagamath S, Dixon DO, et al. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple mycloma. Blood 1990;76:677.
9. deVries EGE, Biesma B, Willemse PHB, et al. A double-blind placebo controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991;51:116.
10. 2) with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) for patient with advanced and chemotherapy refractory urothelium tumors: A phase I study. Proc Am Soc Clin Oncol 1989;8:514.
11. Bunn HF, Recombinant erythropoietin therapy in cancer patients. J Clin Oncol 1990;8:949.
12. James RD, Wilkinson PM, Belli F, et al. Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplalin and carboplatin chemotherapy: Preliminary results. Acta Haematol 1992;87:12.
13. Markman M, Reichman B, Hakes T, et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993;49:172.
14. Hoffman R. Interleukin-3: a potentially useful agent for treating chemotherapy-related thrombocytopenia. J Clin Oncol 1993;11: 2057.
15. D'Hondt V, Weynants P, Humblet U, et al. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study. J Clin Oncol 1993;11:2063.
16. Biesma B, Willemse PHG, Mulder NH, et al. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 1992;80:1141.
17. Postmus PE, Gietema JA, Damsma O, et al. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. J Clin Oncol 1992;10:1131.
18. D'Hondt V, Humblet Y, Guillaume T, et al. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: multicemric placebo-controlled, randomized phase Ib study. Blood 1995;85:2347.
19. Levin J. Thrombopoietin - Clinically Realized? N Engl J Med 1997;336:434.
20. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565.
21. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the C-MpI ligand thrombopoietin. Nature 1994;369:568.
22. Nichol JL, Hokom MM, Hornkohl A, et al. Megakaryocyte growth and development factor: analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995;95:2973.
23. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocytc growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336:404.
24. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-Mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995; 85:1719.
25. Kobuyashi M, Laver JH, Kato T, et al. Thrombopoietin supports proliferation of human primitive hemalopoietic cells in synergy with steel factor and/or interleukin-3. Blood 1996;88:429.
26. de Sauvager FJ, Haas PE, Spencer SD, et al. Stimulation of mega-karyopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533.
27. Eschbach JW.,Abdulhadi MH, Browne JK, et al. Recombinanant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenler clinical trial. Ann Intern Med 1989;111:992.
28. Greenberg PL, Negrin RS, Ginzton N: Granulocyte colony stimulating factor synergises with erythropoietin for enhancing erythroid colony information in myelodysplastic syndromes [Abstract]. Blood 1991;78(suPpl):38.
29. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076.
30. Hammond WP, Kaplan A, Kaplan S, et al. Thrombopoietin (TPO) activates platelets in vitro [Abstract]. Blood 1994;84(suppl):534.
31. Montrucchio G, Brizzi MF, Carusso G, et al. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996;87:2762.
32. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, e-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT 3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995;374:48.
33. Grossman A, Lenos JS, Humes JM, et al. Effects of the combined administration of TPO and G-CSF on recovery from myelosuppression in mice [Abstract]. Blood 1995;86(suppl):371.
34. Ku H, Hirayama F, Kato T, et al. Soluble thrombopoietin receptor (Mpl) and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand for Flt3/Flk2. Blood 1996;88:4124.
35. Kaplan S, Kaplan A, Marcoc K, et al. Citric acid enhances the antithrombotic effects of aspirin in many aspirin-resistant subjects. Clin Appl Thromb Hemost 1997;3:54.
36. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927.
37. Oda A, Miyakawa Y, Druker B, et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996;87:4664.
38. Shimoda K, Okamura S, Harada N, et al. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993;91:1310.
39. Wun T, Paglieroni T, Hammond WP, et al. Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. Am J Hematol 1997;54:225.
40. Oleksowicz L, Mrowiec Z, Zuckerman D, et al. Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism. Thromb Haemost 1994;72:302.
41. Hammond WP, Wun T, Kaplan A, et al. High concentrations of thrombopoietin activate platelets in vitro. Clin Appl Thromb Hemost 1998;4:170.
42. Ballmaier M, Strauss G, Lynen S, et al. Expression of megakaryocyte growth and development factor mRNA in human tissues and detection of MGDF in sera from healthy individuals and patients with thrombocytopenia. Exp Hematol 1995;23:823.
43. Toombs CF, Lott FD, Nelson AG, et al. Megakaryocyte growth and development factor (MGDF) promotes platelet production in vivo without affecting in vivo thrombosis [Abstract]. Blood 1995; 86(suppl):369.
44. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996;87:1833.
45. O'Malley CJ, Rasko JEJ, Basser KM, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996;88:3288.